New Compound Developed to Combat Drug-Resistant Prostate Cancer
Overview of Prostate Cancer
Prostate cancer arises when abnormal cells form in the prostate gland and is recognized as the second leading cause of cancer mortality among men in the United States. According to the American Cancer Society, over 161,000 new cases were projected for 2018, leading to approximately 26,700 deaths. While the exact cause of prostate cancer remains unknown, risk factors include older age, family history, obesity, and exposure to specific chemicals. The disease predominantly affects men aged 65 and older. In its early stages, prostate cancer may not present symptoms, but late-stage signs can include difficulties urinating, reduced urine flow, blood in semen, sexual dysfunction, and pain.
Challenges with Current Treatment Options
The androgen receptor is crucial for the initiation and progression of prostate cancer. Androgen deprivation therapy has been the standard treatment, with newer antiandrogen medications such as Xtandi and Zytiga offering modest improvements in life expectancy. However, many patients develop resistance to these treatments, leading to a state known as metastatic castration-resistant prostate cancer, where the disease continues to progress.
Breakthrough in Research
A recent study published in Nature Communications highlights a significant advancement by a research team from New York University. They developed a novel compound that inhibits the protein interactions that contribute to drug-resistant prostate cancer. Unlike traditional androgen deprivation therapies that focus on the androgen receptor, this innovative compound aims to disrupt protein-protein interactions, thereby preventing the activation of genes responsible for cell proliferation.
Promising Results from Laboratory Studies
The research team conducted tests using prostate cancer cell lines to assess the compound’s efficacy. Their findings revealed that the new compound reduced the proliferation of prostate cancer cells by an impressive 95% over a 22-day period compared to untreated cells. Additionally, the compound was shown to effectively block beta-catenin signaling in live zebrafish, without adversely affecting the development of zebrafish embryos.
Future Implications
This groundbreaking study paves the way for potential advancements in prostate cancer therapy. Further animal testing will be essential to evaluate the therapeutic potential of the new compound in rodent models.
Reference
Schneider J.A. et al. Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer. Nature Communications, 2018;9:4396. DOI: 10.1038/s41467-018-06845-3.